Abbott Labs Beats Earnings Estimates Due To Medical Device Sales


(MENAFN- Baystreet) Tesla's Market Cap Falls Below $500 Billion

  • Kratos Demonstrates Virtualized Ground System
  • Socket Falls on News of New Camera
  • Tesla to Announce Layoffs
  • Charles Schwab's Earnings Narrowly Beat Forecast Previous Articles Subscribe to Get Small Cap News & Alerts Baystreet Staff - Wednesday, April 17, 2024

    Abbott Labs Beats Earnings Estimates Due To Medical Device Sales Abbott Laboratories (ABT) beat Wall Street estimates for its first quarter financial results due to strong sales of its medical devices, notably its glucose-monitoring product.
    The Chicago-based healthcare company announced Q1 earnings per share (EPS) of $0.98 U.S. compared to $0.95 U.S. that was expected among analysts, according to LSEG data.
    Revenue in the January through March quarter totaled $9.96 billion U.S. versus $9.88 billion U.S. that had been forecast on Wall Street.
    The company said that its medical device sales amounted to $4.45 billion U.S., with sales of its glucose monitor“FreeStyle Libre” generating $1.5 billion U.S. in revenue.
    Analysts had anticipated medical device sales of $4.30 billion U.S. in the quarter.
    Abbott Labs' medical device sales have grown in recent quarters due to a resurgence in demand for joint replacements and other surgeries that were delayed during the pandemic.
    In terms of forward guidance, the company said that it now expects a full-year profit of $4.55 U.S. to $4.70 U.S. per share. Wall Street had expected a profit of $4.60 U.S. a share.
    The stock of Abbott Laboratories has increased 5% over the last 12 months to trade at $109.21 U.S. a share.




    • About Us
    • Contact Us
    • Advertise
    • License Our Content
    • Jobs
    • Disclaimer
    • Privacy Policy

    Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks

    MENAFN17042024000212011056ID1108107754


  • Baystreet.ca

    Legal Disclaimer:
    MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.